Patent · US Active

Formulations of RBP4 inhibitors and methods of use

US11951100B2 · kind B2 · utility

0Cited by
17References
20Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 1, 2023
Grant dateApr 9, 2024
Priority date
Expiry dateSep 1, 2043

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07B2200/13
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for the treatment of retinal binding protein (RBP4) related diseases, such as macular degeneration and the like.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.